Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide.

Brad E Morrison | Maria Cecilia Garibaldi Marcondes | Daniel K Nomura | Manuel Sanchez-Alavez | Alejandro Sanchez-Gonzalez | Indrek Saar | Kwang-Soo Kim | Tamas Bartfai | Pamela Maher | Shuei Sugama | Bruno Conti
Journal of immunology (Baltimore, Md. : 1950) | 2012

Inflammation and its mediators, including cytokines and reactive oxygen species, are thought to contribute to neurodegeneration. In the mouse brain, we found that IL-13Rα1 was expressed in the dopaminergic (DA) neurons of the substantia nigra pars compacta, which are preferentially lost in human Parkinson's disease. Mice deficient for Il13ra1 exhibited resistance to loss of DA neurons in a model of chronic peripheral inflammation using bacterial LPS. IL-13, as well as IL-4, potentiated the cytotoxic effects of t-butyl hydroperoxide and hydrogen peroxide on mouse DA MN9D cells. Collectively, our data indicate that expression of IL-13Rα1 on DA neurons can increase their susceptibility to oxidative stress-mediated damage, thereby contributing to their preferential loss. In humans, Il13ra1 lies on the X chromosome within the PARK12 locus of susceptibility to Parkinson's disease, suggesting that IL-13Rα1 may have a role in the pathogenesis of this neurodegenerative disease.

Pubmed ID: 23169588

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

  • Agency: NIDA NIH HHS, United States
    Id: DA030908
  • Agency: NIMH NIH HHS, United States
    Id: R01 MH048866
  • Agency: NIA NIH HHS, United States
    Id: AG028040
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS084869
  • Agency: NIMH NIH HHS, United States
    Id: R29 MH048866
  • Agency: NIDA NIH HHS, United States
    Id: R03 DA027936
  • Agency: NIDA NIH HHS, United States
    Id: K99 DA030908
  • Agency: NIDA NIH HHS, United States
    Id: R00 DA030908
  • Agency: NIA NIH HHS, United States
    Id: R01 AG028040
  • Agency: NIMH NIH HHS, United States
    Id: MH48866

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-Tyrosine Hydroxylase Antibody (antibody)

RRID:AB_390204

This polyclonal targets Tyrosine Hydroxylase

View all literature mentions